Skip to main content
Terug
SZUKF logo

Suzuken Co., Ltd.

Datakwaliteit: 100%
Overbought
SZUKF
OTC Healthcare Medical - Distribution
€ 30,30
€ 0,00 (0,00%)
Marktkapitalisatie: 1,72B
Dagbereik
€ 30,30 € 30,30
52-Weeksbereik
€ 30,30 € 30,30
Volume
100
50D / 200D Gem.
€ 30,30 / € 30,30
Vorige Slotkoers
€ 30,30

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 8,4 3,8
Net Margin % 1,4 3,9
Rev Growth 5Y % 3,1 10,0
D/E 0,0 0,2

Belangrijkste Punten

Revenue grew 3,05% annually over 5 years — modest growth
Earnings grew 18,89% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -83,73B
P/E of 0,05 — trading at a low valuation
PEG of 0,37 suggests growth is underpriced

Groei

Revenue Growth (5Y)
3,05%
Revenue (1Y)0,56%
Earnings (1Y)18,89%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
8,38%
ROIC6,84%
Net Margin1,44%
Op. Margin1,55%

Veiligheid

Debt / Equity
0,00
Current Ratio1,24
Interest Coverage905,49

Waardering

P/E Ratio
0,05
P/B Ratio0,00
EV/EBITDA-2,72
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 0,56% Revenue Growth (3Y) 1,82%
Earnings Growth (1Y) 18,89% Earnings Growth (3Y) 30,21%
Revenue Growth (5Y) 3,05% Earnings Growth (5Y) 44,58%
Profitability
Revenue (TTM) 2,40T Net Income (TTM) 34,50B
ROE 8,38% ROA 3,10%
Gross Margin 8,01% Operating Margin 1,55%
Net Margin 1,44% Free Cash Flow (TTM) -83,73B
ROIC 6,84% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 1,24
Interest Coverage 905,49 Dividend Yield 0,02%
Valuation
P/E Ratio 0,05 P/B Ratio 0,00
P/S Ratio 0,00 PEG Ratio 0,37
EV/EBITDA -2,72 Dividend Yield 0,02%
Market Cap 1,72B Enterprise Value -100,94B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,40T 2,39T 2,31T 2,23T 2,13T
Net Income 34,50B 29,02B 20,35B 14,39B 7,90B
EPS (Diluted) 454,58 357,87 236,46 163,18 88,51
Gross Profit 192,23B 185,25B 179,70B 160,99B 157,84B
Operating Income 37,13B 34,88B 32,61B 20,12B 9,16B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,11T 1,23T 1,15T 1,14T 1,11T
Total Liabilities 706,41B 812,26B 734,57B 723,66B 696,51B
Shareholders' Equity 407,29B 416,31B 411,21B 417,69B 417,05B
Total Debt 0,0 1,80B 1,80B 2,12B 2,28B
Cash & Equivalents 102,66B 181,83B 109,03B 141,38B 151,12B
Current Assets 844,10B 948,29B 878,17B 882,94B 859,73B
Current Liabilities 679,11B 784,42B 711,27B 697,88B 670,07B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Value Defensive Investing (Benjamin Graham)
#705 of 708
0

Recente Activiteit

Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026